HONG KONG – Tetraphase Pharmaceuticals Inc., of Watertown, Mass., said its Chinese partner, Everest Medicines Ltd., has filed an application with Chinese regulators to initiate the phase III trial of its lead product eravacycline in complicated intra-abdominal infections (cIAIs).
HONG KONG – Israeli biotech firm Atox Bio Inc., of Ness Ziona, is moving ahead with its lead product, reltecimod (AB-103), with two clinical trials ongoing in parallel in the U.S. The funds from the financing round last December will help speed up the development of the drug candidate, pushing it closer to approval in two year's time.
HONG KONG – South Korea is striving to be a global hub for biosimilars, as domestic biopharma firms such as Celltrion Inc., Samsung Bioepis Co. Ltd. and LG Chem Ltd. are all spearheading their biosimilars development.
HONG KONG – China's Luye Pharma Group Ltd. has partnered up with U.S. biotech firm Elpis Biopharmaceuticals Corp. to work on dual target-based therapies for cancer patients who fail to respond to current treatment.
HONG KONG – South Korea is striving to be a global hub for biosimilars, as domestic biopharma firms such as Celltrion Inc., Samsung Bioepis Co. Ltd. and LG Chem Ltd. are all spearheading their biosimilars development.
HONG KONG – China's Luye Pharma Group Ltd. has partnered up with U.S. biotech firm Elpis Biopharmaceuticals Corp. to work on dual target-based therapies for cancer patients who fail to respond to current treatment.
HONG KONG –Israeli biotech firm Atox Bio Inc., of Ness Ziona, is moving ahead with its lead product, reltecimod (AB-103), with two clinical trials ongoing in parallel in the U.S. The funds from the financing round last December will help speed up the development of the drug candidate, pushing it closer to approval in two year's time.
HONG KONG – China's contract drugmaking giant, Wuxi Biologics Inc., of Wuxi city, is actively expanding its global footprint, announcing plans to work with its Canadian partner on a brain cancer drug and opening its 10th global manufacturing facility in Singapore.
HONG KONG – Newly launched Chinese biotech Brii Biosciences is looking to use an experienced management team, partnerships and $260 million in initial funding to bring innovative medicines to its home market faster. Its initial focus will be infectious diseases.
